Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.78 |
| ▸ | SLC5A1 | P13866 | 17/20 | 0.78 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.66 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14567829 | 1.00 | SLC5A2 (0.78) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13380376 | 1.00 | SLC5A2 (0.78) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14572683 | 1.00 | SLC5A2 (0.78) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13395782 | 1.00 | SLC5A2 (0.78) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13380364 | 0.95 | SLC5A2 (0.80) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL13380363 | 0.95 | SLC5A2 (0.80) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14567635 | 0.95 | SLC5A2 (0.80) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL2863224 | 0.95 | SLC5A2 (0.80) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL14572633 | 0.95 | SLC5A2 (0.80) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| SCHEMBL1457108 | 0.93 | SLC5A2 (0.82) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081625-A1 | METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | US | disclosed |
| US-7683160-B2 | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-23 | — | — | US | disclosed |
| US-20070049537-A1 | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081625-A1 | METHODS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISORDERS | HTT, SNCA, PSEN2 | SLC5A2 59/4885SLC5A1 41/4885ADRA2A 2392/4885 |
| US-20070049537-A1 | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | UGGT1, UGT2B7, G6PD | SLC5A2 8/4885SLC5A1 5/4885ADRA2A 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.